Enyedy Mark J
SEC-identified person · CIK 1586965 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Biomarin Pharmaceutical INC BMRN | Director | filed 2023–2026 |
| Charles River Laboratories International, INC. CRL | Director | filed 2025–2026 |
| Immunogen, Inc. IMGN | Director · Chief Executive Officer | filed 2016–2024 |
| Logicbio Therapeutics, Inc. LOGC | Director | filed 2020–2022 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2018–2020 |
| Keryx Biopharmaceuticals INC KERX | Director | filed 2017–2018 |
| Fate Therapeutics INC fate | Director | filed 2013–2017 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.